Kura Oncology will host a virtual investor event on December 8, 2025, at 12:30 PM ET to discuss data on the triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The data are scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.
The event will feature the company’s management team and lead investigators. A live webcast and replay will be available on Kura Oncology’s website under the Investors tab in the Events and Presentations section.
Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment. Its pipeline includes small molecule drug candidates targeting cancer signaling pathways in hematologic malignancies and solid tumors. Kura developed and commercializes KOMZIFTI™, an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. The company continues to advance menin inhibition and farnesyl transferase inhibition therapies.
For more information, visit kuraoncology.com.
Leave a Reply